ROCKVILLE, Md.--(BUSINESS WIRE)-- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company will be participating in the following investor conferences in October 2010.
- The 9thAnnual BIO Investor Forum
San Francisco, CA.
October 5, 2010
Corporate Overview Presentation
9:00 AM Pacific
[The presentation, which will include a discussion of the Company’s business activities, financial outlook and current news, will be webcast live.]
- The 17thAnnual BioCentury/Thomson Reuters Newsmakers in the Biotech Industry Conference
New York, NY.
October 22, 2010
Corporate Overview Presentation
2:00 PM Eastern
[The presentation, which will include a discussion of the Company’s business activities, financial outlook and current news, will be webcast live.]
Both webcasts will be accessible from the Emergent website www.emergentbiosolutions.com under “Investors”.
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and antibody therapies that assist the body’s immune system to prevent or treat disease. Emergent’s marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. Emergent’s product pipeline targets infectious diseases and includes programs focused on anthrax, tuberculosis, typhoid, flu and chlamydia. Additional information may be found at www.emergentbiosolutions.com.
CONTACT:
Emergent BioSolutions Inc.
Investors Contact:
Robert G. Burrows
Vice President, Investor Relations
301-795-1877
[email protected]
or
Media Contact:
Tracey Schmitt
Vice President, Corporate Communications
301-795-1800
[email protected]
KEYWORDS: United States North America California Maryland New York
INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical Other Health General Health
MEDIA:
Logo |